| OAB0104 | Pharmacokinetics, safety, and efficacy of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in virologically suppressed pregnant women with HIV | Oral abstract session with live Q&A | Antiretroviral therapies and clinical issues in adults |
| OAB0105 | Virological dynamics among children living with HIV transitioned to a dolutegravir-based regimen in Nigeria | Oral abstract session with live Q&A | Antiretroviral therapies and clinical issues in infants, children and adolescents |
| OAB0202 | Prior M184V/I and multiple prior virological failures have no impact on the efficacy of switching HIV+ adults to DTG/3TC through 96Wks in SOLAR-3D | Oral abstract session with live Q&A | Antiretroviral therapies and clinical issues in adults |
| OAB0203 | Weight and body composition after switch to doravirine/islatravir (DOR/ISL) 100/0.75mg once daily: week 48 results from 2 randomized active-controlled phase 3 trials, MK8591A-017 (P017) and MK8591A-018 (P018) | Oral abstract session with live Q&A | Clinical complications of HIV and antiretroviral therapy |
| OAB0204 | High rates of long-term HIV RNA re-suppression after virological failure on dolutegravir in the ADVANCE trial | Oral abstract session with live Q&A | Antiretroviral therapies and clinical issues in adults |
| OAB0205 | Lenacapavir oral bridging maintains efficacy with a similar safety profile when SC LEN cannot be administered | Oral abstract session with live Q&A | Antiretroviral therapies and clinical issues in adults |
| OAB0302 | HIV among mpox cases: clinical characteristics and outcomes in the WHO global surveillance 2022 | Oral abstract session with live Q&A | Co-infections (including opportunistic infections) |
| OAB0303 | High rate of hepatitis C and reinfection after direct-acting antiviral treatment among men-who-have-sex-with-men living with HIV in Bangkok, Thailand | Oral abstract session with live Q&A | Co-infections (including opportunistic infections) |
| OAB0304 | Short-course rifapentine-based regimens for latent tuberculosis infection among people living with HIV who received integrase inhibitor-based antiretroviral therapy | Oral abstract session with live Q&A | Co-infections (including opportunistic infections) |
| OAB0305 | Co-infection of High-Risk Human Papillomavirus and Human T-Lymphotropic Virus-1 among women living with HIV on Antiretroviral Therapy at a Tertiary Hospital in Kenya | Oral abstract session with live Q&A | Co-infections (including opportunistic infections) |